No Cover Image

Journal article 144 views 25 downloads

Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study

Sharmistha Roy Chowdhury, Fethi Sadouki, Edward Collins, Frederick Keen, Ridhi Bhagi, Yuan S. J. Lim, Silviu L. Cozma, Steve Bain Orcid Logo

Diabetes Therapy, Volume: 15, Issue: 4, Pages: 869 - 881

Swansea University Author: Steve Bain Orcid Logo

  • 65730.VoR.pdf

    PDF | Version of Record

    © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

    Download (803.04KB)

Check full text

DOI (Published version): 10.1007/s13300-024-01551-4

Abstract

IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to ga...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa65730
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: IntroductionSemaglutide, the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) available in subcutaneous and oral formulation for treatment of type 2 diabetes (T2D), has demonstrated clinically significant improvements in glycaemic control and weight in clinical trials. This study aimed to gain insights into the use of both formulations and evaluate their clinical effectiveness in a secondary care clinic in Wales.MethodsThis was a retrospective observational analysis of adults with T2D initiated on oral or subcutaneous semaglutide. Changes from baseline in glycated haemoglobin (HbA1c), weight and other metabolic parameters were evaluated.ResultsAt baseline, participants (n = 103) had a mean age of 57.3 years, mean HbA1c of 79.1 mmol/mol (9.38%), mean weight of 111.8 kg and body mass index (BMI) of 39.6 kg/m2 (no statistically significant differences between oral and subcutaneous groups). At 6-month follow-up, statistically significant improvements in HbA1c (− 19.3 mmol/mol [− 1.77%] and − 20.8 mmol/mol [− 1.90%]), body weight (− 9.0 kg and − 7.2 kg), and BMI (− 3.3 kg/m2 and − 2.5 kg/m2) were observed for oral and subcutaneous semaglutide, respectively. No statistically significant differences between the formulations were observed, and safety profiles were comparable.ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D.
Keywords: GLP-1 RA; Primary care; Realworld evidence; Secondary care; Semaglutide; Type 2 diabetes
College: Faculty of Medicine, Health and Life Sciences
Funders: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Medical writing and data analysis support and the journal’s rapid service fee was paid for by Novo Nordisk.
Issue: 4
Start Page: 869
End Page: 881

Similar Items